Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning

The increasing appreciation of oncogenic driver alterations in non-small cell lung cancer (NSCLC) has resulted in a rapid expansion of therapeutic compounds. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations are the prototypical examples and have driven the par...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Lung Cancer Res
Hlavní autoři: Klempner, Samuel J., Raufi, Alexander, Ou, Sai-Hong Ignatius
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2015
Témata:
Editorial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4630509/
https://ncbi.nlm.nih.gov/pubmed/26629439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky